14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
VRXA vs YDES: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, YD Bio Limited (YDES) is the stronger overall head-to-head candidate over VRXA (VRXA) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). VRXA carries a Unified Composite Score of 41.6/100 (SELL) at $1.04 (N/M Forward P/E, N/A operating margin), whereas YDES carries 49.0/100 (HOLD) at $4.83 (N/M Forward P/E, -528.7% operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VRXA vs YDES. Trailing 12-month operating profitability (VRXA N/A vs YDES -528.7%) and valuation multiples (VRXA N/M vs YDES N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $323.0M market capitalization and -528.7% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ VRXA vs YDES Key Questions & Quantitative Answers
As of Nov 20, 2026, YD Bio Limited (YDES) is the stronger overall head-to-head candidate over VRXA (VRXA) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). VRXA carries a Unified Composite Score of 41.6/100 (SELL) at $1.04 (N/M Forward P/E, N/A operating margin), whereas YDES carries 49.0/100 (HOLD) at $4.83 (N/M Forward P/E, -528.7% operating margin). Technically, VRXA sits in a Neutral phase (RSI 46.0, UNCLASSIFIED options structure) and YDES sits in a Neutral phase (RSI 43.6, UNCLASSIFIED options structure).
YDES leads the Growth & Scale pillar: VRXA posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with YDES at +314.9% YoY revenue growth and +0.0% YoY earnings growth on $1.2M TTM revenue (29.6% gross margin, -528.7% operating margin). On trailing 12-month operating scale, VRXA generates N/A in USD-normalized revenue versus $1.2M for YDES. In operating R&D and SG&A reinvestment, VRXA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for YDES.
VRXA and YDES trade at balanced relative valuation multiples. VRXA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas YDES trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VRXA (N/A ROE) versus YDES (-42.7% ROE) capital efficiency.
In options market volatility and institutional positioning, VRXA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.16β · 104% Vol realized risk). By comparison, YDES carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.07β · 139% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.